| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5703219 | American Journal of Ophthalmology | 2017 | 19 Pages |
Abstract
Subretinal delivery of rAAV.sFLT-1 was well tolerated and demonstrated a favourable safety profile through month 36. Thus, rAAV.sFLT-1 could be safely considered for future evaluation in the treatment of wet AMD.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Ian J. Constable, Chooi-May Lai, Aaron L. Magno, Martyn A. French, Samuel B. Barone, Steven D. Schwartz, Mark S. Blumenkranz, Mariapia A. Degli-Esposti, Elizabeth P. Rakoczy,